Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biochemistry ; 40(1): 241-8, 2001 Jan 09.
Artigo em Inglês | MEDLINE | ID: mdl-11141076

RESUMO

Recently, we showed that S100A8/A9 were secreted from phorbol ester-stimulated neutrophil-like HL-60 cells, thereby carrying arachidonic acid [Kerkhoff et al. (1999) J. Biol. Chem. 274, 32672-32679]. The present study was undertaken to evaluate whether the secreted S100A8/A9-AA complex might be involved in transcellular eicosanoid metabolism. In the presence of S100A8/A9, arachidonic acid was rapidly taken up by human umbilical vein endothelial cells in a saturable and energy-dependent fashion. Protein-facilitated arachidonate uptake was confirmed by its sensitivity toward the protein modifiers bromobimane and phloretin. Both potassium and sodium depletion did not affect the arachidonate transport, indicating that arachidonate influx was independent of endocytosis. The uptake of exogenous arachidonic acid by HUVEC was predominantly mediated by FAT/CD36. This conclusion was drawn by the findings that (i) arachidonate uptake was drastically inhibited by sulfo-N-succinimidyl oleate, a specific inhibitor of FAT/CD36; (ii) the maximal inhibition of arachidonate uptake induced by SSO was similar to that effected by ATP depletion; and (iii) the arachidonate transport was 2-fold higher in COS-7 cells transfected with the pEF.BOS-CD36 expression vector than in the empty vector-transfected COS-7 cells. Kinetic studies of arachidonate uptake were indicative for an interaction between fatty acid transporter and S100A8/A9-AA complex that was confirmed by an in vitro protein-protein interaction assay. FAT/CD36 has been suggested to be involved in inflammatory responses, and S100A8/A9 are released from activated leukocytes at inflammatory loci. Therefore, it can be envisioned that their interaction might propagate host response by perpetuating recruitment and activation of cellular effectors.


Assuntos
Antígenos de Diferenciação/metabolismo , Ácido Araquidônico/metabolismo , Antígenos CD36/metabolismo , Endotélio Vascular/metabolismo , Ácidos Graxos Essenciais/metabolismo , Proteínas de Membrana , Proteínas de Neoplasias , Receptores Imunológicos/metabolismo , Receptores de Lipoproteínas , Proteínas S100/metabolismo , Proteínas Supressoras de Tumor , Animais , Antígenos de Diferenciação/genética , Ácido Araquidônico/antagonistas & inibidores , Transporte Biológico Ativo/efeitos dos fármacos , Antígenos CD36/genética , Antígenos CD36/fisiologia , Células COS , Calgranulina B , Proteínas de Transporte/fisiologia , Células Cultivadas , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Proteína 7 de Ligação a Ácidos Graxos , Proteínas de Ligação a Ácido Graxo , Ácidos Graxos Essenciais/antagonistas & inibidores , Humanos , Cinética , Substâncias Macromoleculares , Ácidos Oleicos/farmacologia , Receptores Imunológicos/antagonistas & inibidores , Receptores Imunológicos/genética , Receptores Imunológicos/fisiologia , Receptores Depuradores , Proteínas S100/genética , Receptores Depuradores Classe B , Succinimidas/farmacologia , Transfecção
2.
Br J Pharmacol ; 109(4): 972-9, 1993 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8401950

RESUMO

1. The aims of this study were first, to examine whether deficits in nerve conduction in streptozotocin-diabetic rats could be reversed by a 10% dietary supplement of evening primrose oil. Second, to determine the time-course of reversal, and third, to assess whether the effects could be blocked by the cyclo-oxygenase inhibitor flurbiprofen (5 mg kg-1 day-1). 2. One-month diabetes produced 20% and 15% deficits in sciatic motor and saphenous sensory conduction velocity respectively, which were maintained over 2 months diabetes. 3. The effect of 1-month evening primrose oil treatment on abnormalities caused by an initial month of untreated diabetes was examined. Motor and sensory nerve conduction velocity were restored to the non-diabetic level. 4. Resistance to hypoxic conduction failure was investigated for sciatic nerve trunk in vitro. The 80% conduction failure times were 29% and 55% prolonged by 1- and 2-month diabetes respectively. Evening primrose oil did not reverse the increased hypoxic resistance following 1-month untreated diabetes. 5. Sciatic nerve endoneurial capillary density was not significantly affected by diabetes, but was 16% increased in diabetic rats with reversal by evening primrose oil treatment for 1 month compared to 2-month untreated diabetes. 6. Serial motor conduction velocity measurement after 3-month untreated diabetes revealed complete normalization by evening primrose oil within 4 days. Cessation of treatment resulted in a rapid decline in conduction velocity over 24 h. 7. In a preventive study of 2-month duration, 6 groups of rats were used. These comprised non-diabetic controls, diabetic rats, and evening primrose oil-treated diabetic rats, both with and without flurbiprofen treatment. Flurbiprofen had no significant effect in non-diabetic rats, but produced an 11% worsening of motor conduction velocity and a 21% reduction of sciatic capillary density in diabetic rats. Evening primrose oil prevented the decreases in conduction velocity and increased hypoxic resistance with diabetes, and caused a 23% increase in capillary density. Flurbiprofen completely blocked the effect of evening primrose oil on conduction velocity, resistance to hypoxia, and capillarization.8. Six main conclusions were reached. First, evening primrose oil rapidly reverses conduction deficits in diabetic rats. Second, the effects of treatment may be very short-lived, suggesting a primary metabolic action. Third, evening primrose oil cannot reverse established changes in hypoxic resistance over 1-month treatment. Fourth, long-term treatment causes angiogenesis, suggesting a vascular action. Fifth,products of cyclo-oxygenase-mediated metabolism are necessary for maintaining vasa nervorum integrity in diabetic rats. Sixth, evening primrose oil probably acts by providing substrate for vasodilator prostanoid synthesis by vasa nervorum.


Assuntos
Capilares/efeitos dos fármacos , Inibidores de Ciclo-Oxigenase/farmacologia , Diabetes Mellitus Experimental/fisiopatologia , Ácidos Graxos Essenciais/farmacologia , Flurbiprofeno/farmacologia , Neurônios/efeitos dos fármacos , Potenciais de Ação/efeitos dos fármacos , Animais , Peso Corporal/efeitos dos fármacos , Ácidos Graxos Essenciais/antagonistas & inibidores , Hipóxia/fisiopatologia , Ácidos Linoleicos , Masculino , Neurônios Motores/efeitos dos fármacos , Condução Nervosa/efeitos dos fármacos , Neurônios Aferentes/efeitos dos fármacos , Oenothera biennis , Nervo Fibular/irrigação sanguínea , Nervo Fibular/efeitos dos fármacos , Óleos de Plantas , Prostaglandinas/metabolismo , Ratos , Ratos Sprague-Dawley , Fluxo Sanguíneo Regional/efeitos dos fármacos , Nervo Isquiático/irrigação sanguínea , Nervo Isquiático/efeitos dos fármacos , Ácido gama-Linolênico
3.
Prostaglandins Med ; 1(4): 283-91, 1978 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-715066

RESUMO

Experimental allergic encephalomyelitis in Lewis rats was suppressed by treatment with essential fatty acids (EFA) given perorally. This treatment effect could be abolished by administration of a drug (Indomethacin) known to inhibit biosynthesis of certain prostaglandins from EFA. This observation suggests that the suppressive effect of EFA on cell-mediated immune reactions is brought about by EFA-derived prostaglandins.


Assuntos
Encefalomielite Autoimune Experimental/tratamento farmacológico , Ácidos Graxos Essenciais/antagonistas & inibidores , Indometacina/farmacologia , Animais , Encefalomielite Autoimune Experimental/patologia , Ácidos Graxos Essenciais/uso terapêutico , Feminino , Masculino , Ratos
5.
Proc Natl Acad Sci U S A ; 69(8): 2125-9, 1972 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-4559596

RESUMO

The activity of the methylgalactoside transport system of E. coli is impaired upon treatment with 3-decynoyl-N-acetylcysteamine, an inhibitor of unsaturated fatty-acid synthesis. Treated cells are unable to be induced for permease activity, while transport sites synthesized before treatment show a regular loss of activity. The inhibition of methylgalactoside transport occurs at a step after translation of the galactose-binding protein, a component of the permease, and appears to be highly specific, since drug-treated cells show normal viability, protein synthesis, and membrane integrity when transport activity is greatly reduced. A second transport system, the galactoside permease, shows significantly less sensitivity to the inhibitor. That the activity of this permease is maintained in the presence of this inhibitor suggests that the inhibitor does not impair energy coupling.


Assuntos
Cisteamina/farmacologia , Escherichia coli/metabolismo , Ácidos Graxos Essenciais/antagonistas & inibidores , Galactose/metabolismo , Transporte Biológico Ativo/efeitos dos fármacos , Isótopos de Carbono , Fracionamento Celular , Membrana Celular/efeitos dos fármacos , Sobrevivência Celular , Cromatografia em Papel , Indução Enzimática/efeitos dos fármacos , Escherichia coli/crescimento & desenvolvimento , Fucose/metabolismo , Genótipo , Lactose/metabolismo , Proteínas de Membrana Transportadoras/análise , Métodos , Ligação Proteica , Biossíntese de Proteínas , Proteínas/análise , Sulfatos/metabolismo , Isótopos de Enxofre , Trítio
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...